Apotex Inc. v. AstraZeneca Canada Inc., 2017 FC 545 (Esomeprazole*)
Justice Locke - 2017-06-02
Read full decision. Automatically generated summary:
This order concerns disputes between the parties (referred to herein as Apotex and AstraZeneca) arising from the reading in at trial of passages from examinations for discovery as contemplated in Rule 288 of the Federal Courts Rules, SOR/98-106 [the Rules]. These disputes, which were argued during the trial, fall into two categories: With regard to certain of Apotex’s proposed read-ins, AstraZeneca seeks to add qualifying answers under Rule 289; With regard to certain of AstraZeneca’s proposed read-ins, Apotex objects to their inclusion. ... For the reasons set out above, I will not interfere in any way with the proposed read-ins. I will not order Apotex to include any qualifying answers in its read-ins. Also, I will not order any of AstraZeneca’s read-ins to be excluded.
Decision relates to:
- T-1668-10 - ASTRAZENECA CANADA INC. ET AL v. APOTEX INC.
- T-389-11 - APOTEX INC. v. ASTRAZENECA CANADA INC.